Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus’ strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with Seikagaku to exclusively distribute SUPARTZ FX™ in the U.S. through May 2028. Further, in January, Bioventus contributed $2.5MM in funding for CartiHeal’s ongoing clincial study of the Agili-C™ inorganic calcium carbonate scaffold implant for the treatment of joint surface lesions.
Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus' strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with...
Bioventus and LifeLink Tissue Bank entered an agreement to co-develop next-gen bone allograft for spine and trauma applications.
The partnership supports Bioventus’ strategy to grow sales of orthobiologic products—both existing and those to-be-developed.
For instance, earlier this month, the company announced an extension of its agreement with Seikagaku to exclusively distribute SUPARTZ FX™ in the U.S. through May 2028. Further, in January, Bioventus contributed $2.5MM in funding for CartiHeal’s ongoing clincial study of the Agili-C™ inorganic calcium carbonate scaffold implant for the treatment of joint surface lesions.
Copy to clipboard 
